Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6119628 | Journal of Clinical Virology | 2016 | 14 Pages |
Abstract
Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Hiroyuki Takamatsu, Raita Araki, Ryosei Nishimura, Akihiro Yachie, J. Luis Espinoza, Hirokazu Okumura, Takashi Yoshida, Kiyotaka Kuzushima, Shinji Nakao,